Congress taking place in New Orleans, LA, from September 14-19. The Company will debut Change the Tune in TRD, a new educational campaign for U.S. HCPs focused on TRD, and present new HEOR data examining the burden of TRD alongside encore presentations from its COMP360 psilocybin clinical development program.

Change the Tune in TRD: Advancing HCP Education

Change the Tune in TRD is a new educational initiative for U.S. HCPs exploring the neurobiology and navigating care pathways in TRD. The campaign will be debuted in a three-panel Innovation Theater on September 15th from 12:15-1:30pm in Room 220-222. The featured panelists include:

  • Saundra Jain MA, PsyD, LPC, Psychotherapist, Adjunct Clinical Affiliate, University of Texas at Austin School of Nursing; Private Practice, Austin, Texas
  • Bryan B. Shapiro MD MPH, Board-Certified Psychiatrist, Assistant Clinical Professor of Psychiatry, UC Irvine Medical Center
  • Sandhya Prashad, MD, Interventional Psychiatrist, Founder and medical director of Sandhya J. Prashad, MD, Houston Ketamine Therapeutics, and Houston TMS Therapeutics

New HEOR Data

  • Real-World Healthcare Costs and Resource Utilization Across Health States Among Patients with Treatment-Resistant Depression – presented by Yechu Hua, poster #186
  • Characterization of Depression Episodes to Inform Real-World Health States for Major Depressive Disorder and Treatment-Resistant Depression – presented by Vicki Wing, poster #88
  • Behavioral Health Provider Perspectives on Management of Individuals with TRD – presented by Caroline Hostetler, poster #95
  • Identifying Treatment-Resistant Depression in the Real-World: Clinical Practice and Barriers to Care – presented by Matthew Sidovar, poster #89

Encore COMP360 Presentations

  • Demographic and Clinical Characteristics of Participants Receiving COMP360 Psilocybin Treatment for Treatment-Resistant Depression Across Two Pivotal Phase 3 Trials –​ presented by Kevin Loh, poster #93
  • Durability of Efficacy and Safety of COMP360 Psilocybin for Treatment-resistant Depression Across 26 Weeks in a Double-blind, Randomised, Controlled Phase 3 Study​​ – presented by Collin Challis, poster #92
  • Efficacy and Safety of COMP360 Psilocybin for ​Treatment-resistant Depression (TRD) in Two Phase 3, ​Double-blind, Randomized, Controlled Studies – presented by Juliana Gassmann, poster #91